BeaconEquity.com: STEM losses $5.2M in fourth-quarter of 2009

BeaconEquity.com announces an investment report featuring biotech company StemCells Inc. (Nasdaq:STEM). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

It is available at: http://www.beaconequity.com/i/STEM

Get our alerts BEFORE the rest of the market.  Follow us on Twitter: https://twitter.com/BeaconEquity

StemCells Inc. (STEM) is a biopharmaceutical company engaged in the discovery and development of cell-based therapeutics to treat damage to, or degeneration of, major organ systems. The Company has two product development programs: CNS Program, which is developing applications for its human neural stem cell, and Liver Program, which is developing applications for its human liver engrafting cells. In addition, it is conducting preclinical work for spinal cord injury, myelin disorders and retinal disorders.  

Message Board Search for STEM:  http://www.boardcentral.com/boards/STEM

In the report, the analyst notes:

"STEM recently posted its fourth-quarter results, gaining revenue from its acquisition of Stem Cell Sciences PLC in April in a cash and stock deal. In the fourth quarter, STEM said it lost $5.2 million, or $(0.05) per share. A year ago, the Company posted a loss of $10.1 million, or $(0.011) per share. Its revenue more than doubled to $418,000 from $172,000.

"In February the Company announced the launch of GS2-M(TM), a new cell culture medium that enables the derivation and long-term maintenance of true (germline competent) mouse induced pluripotent stem (iPS) cells. GS2-M is part of the Company's growing SC Proven^(R) line of specialty cell culture products."